Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 304

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 304
---
 grants from the National Institutes of Health (NIH) in the total amount of approximately $3.86 million. The National Institute on Aging (NIA) awarded the company approximately $3.36 million in a Commercialization Readiness Pilot (CRP) grant as part of its Small Business Innovation Research (SBIR) program. The award builds upon earlier studies conducted by DiamiR in collaboration with leading academic centers and continues to support development of CogniMIR ®, the company’s lead diagnostic product candidate for early detection and monitoring of mild cognitive impairment and AD. The second award of $498,572 was granted to DiamiR by the National Institute for Neurological Disorders and Stroke (NINDS) for a project entitled “Circulating Organ -enrichedmicroRNAs as biomarkers of Rett Syndrome.” Stock-based compensation Stock -basedcompensation for acquiring goods or providing services is recognized at fair value when the goods are obtained or over the service period. If the award contains performance conditions, the measurement date of the award is the earlier of the date at which a commitment for performance by the non -employeeis reached or the date at which performance is reached. A performance commitment is reached when performance by the non -employeeis probable because of sufficiently large disincentives for nonperformance. DiamiR issued 44,000 restricted stock units (“RSUs”) in the fiscal year ending May 31, 2023 as consideration for consulting services received from third parties, subject to certain vesting conditions. No compensation expense related to the RSUs was recognized in the years ended May 31, 2024 or May 31, 2023, as the vesting condition was not considered to be probable of achievement for accounting purposes. On August 31, 2023, the 44,000 RSUs were canceled. DiamiR also issued 140,000 options as consideration for consulting services received from third parties in the fiscal years ending May 31, 2023, subject to certain vesting conditions. In the year ended May 31, 2024, the 140,000 options were canceled and in their place 153,000 options were issued with amended terms, of which 58,500 options were subsequently forfeited. DiamiR issued 88,000 RSUs and 154,000 stock options in the fiscal year ending May 31, 2023 to our CEO as compensation for services, subject to certain vesting conditions. No compensation expense related to these awards